{"schema_version":"secwatch.filing_event.v1","accession":"0001051514-22-000091","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.427493+00:00","generated_at":"2026-06-22T00:32:51.623640+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"STRATA Q3 2022 revenue $9.4M (+22% YoY); net loss widens; launches TheraClear X","bullets":["Revenue $9.4M vs $7.7M YoY (+22%); equipment revenue $3.6M (+80%); international sales $3.3M (+82%).","Net loss $1.0M ($0.03/sh) vs $0.5M loss ($0.02/sh) in Q3 2021; non-GAAP adjusted EBITDA $1.1M up from $0.9M.","Gross margin 61.6% (GAAP) vs 69.7% YoY; non-GAAP gross margin 67.0% vs 71.6%, impacted by amortization and product mix.","U.S. commercial launch of TheraClear X acne therapy system targeting a $5.5B acne treatment market.","Reiterates FY2022 revenue guidance of $33M–$35M, expects strong double-digit year-over-year growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001051514-22-000091","json":"https://secwatch.observer/filing/0001051514-22-000091.json","markdown":"https://secwatch.observer/filing/0001051514-22-000091.md","text":"https://secwatch.observer/filing/0001051514-22-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:32:51.623640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07a16fed744537ccbff6b5cbc8d5522163beb3ed","claim":"STRATA Skin Sciences, Inc. reported full-year 2022 results: revenue $33 million to $35 million. Guidance reaffirmed.","evidence_excerpt":"The company reiterated its full-year 2022 revenue guidance in the range of $33 million to $35 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2022"},{"label":"Revenue","value":"$33 million to $35 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"883a4e203f9cfa192a4a8f887853d1deed82f796","claim":"STRATA Skin Sciences, Inc. reported third quarter ended September 30, 2022 results: net income $1.0 million, EPS $0.03. Guidance reaffirmed.","evidence_excerpt":"STRATA Skin Sciences Reports Strong Third Quarter 2022 Financial Results ● Strong revenue in the third quarter 2022 of $9.4 million , a 22% increase over the third quarter of 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$1.0 million"},{"label":"EPS","value":"$0.03"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"883a4e203f9cfa192a4a8f887853d1deed82f796","claim":"STRATA Skin Sciences, Inc. reported third quarter ended September 30, 2022 results: net income $1.0 million, EPS $0.03. Guidance reaffirmed.","evidence_excerpt":"Revenues for the third quarter of 2022 were $9.4 million, as compared to revenues of $7.7 million for the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$1.0 million"},{"label":"EPS","value":"$0.03"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"883a4e203f9cfa192a4a8f887853d1deed82f796","claim":"STRATA Skin Sciences, Inc. reported third quarter ended September 30, 2022 results: net income $1.0 million, EPS $0.03. Guidance reaffirmed.","evidence_excerpt":"Net loss for third quarter 2022 was $1.0 million, or a loss of $0.03 per basic and diluted common share, as compared to the net loss for the third quarter of 2021 of $0.5 million, or net loss of $0.02 per basic and diluted common share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$1.0 million"},{"label":"EPS","value":"$0.03"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}